Disclosed herein are electrospun fibrous matrix and its production method. The method mainly includes the steps of, mixing a first polymer and a drug to form a first mixture, and sonicating the first mixture until a plurality of microparticles are formed with the drug encapsulated therein; and mixing the plurality of microparticles with a second polymer to form a second mixture, subjecting the second mixture to a wet electrospinning process to form the electrospun fibrous matrix. The thus-produced electrospun fibrous matrix is characterized by having a plurality of first and second fibrils woven together, in which each second fibril has a plurality of drug-encapsulated microparticles independently integrated and disposed along the longitudinal direction of the second fibril. Also encompassed in the present disclosure is a method for treating a wound of a subject. The method includes applying the present electrospun fibrous matrix to the wound of the subject to accelerate wound healing.

Disclosed herein are electrospun fibrous matrix and its production method. The method mainly includes the steps of, mixing a first polymer and a drug to form a first mixture, and sonicating the first mixture until a plurality of microparticles are formed with the drug encapsulated therein; and mixing the plurality of microparticles with a second polymer to form a second mixture, subjecting the second mixture to a wet electrospinning process to form the electrospun fibrous matrix. The thus-produced electrospun fibrous matrix is characterized by having a plurality of first and second fibrils woven together, in which each second fibril has a plurality of drug-encapsulated microparticles independently integrated and disposed along the longitudinal direction of the second fibril. Also encompassed in the present disclosure is a method for treating a wound of a subject. The method includes applying the present electrospun fibrous matrix to the wound of the subject to accelerate wound healing.

Disclosed herein is a technology platform for delivering macromolecules of interest to a subject over a period of time without repeated administration. The compositions disclosed herein are comprised of genetically modified cells, engineered exosomes, and adhesive scaffold materials. The compositions are designed to sustain the supply macromolecules of interest at a site of administration for a long period of time ranging from days to months.

Disclosed herein is a technology platform for delivering macromolecules of interest to a subject over a period of time without repeated administration. The compositions disclosed herein are comprised of genetically modified cells, engineered exosomes, and adhesive scaffold materials. The compositions are designed to sustain the supply macromolecules of interest at a site of administration for a long period of time ranging from days to months.

In some aspects, disclosed herein are methods and compositions for treatment of erectile dysfunction using regenerative fibroblasts or cells derived from fibroblasts. Methods and compositions disclosed also include those for generating regenerative fibroblast cells from fibroblasts. Also disclosed are methods and compositions for treatment of erectile dysfunction using regenerative fibroblast-conditioned media. Regenerative fibroblast cells generated from fibroblasts and regenerative fibroblast-conditioned media are also described.

In some aspects, disclosed herein are methods and compositions for treatment of erectile dysfunction using regenerative fibroblasts or cells derived from fibroblasts. Methods and compositions disclosed also include those for generating regenerative fibroblast cells from fibroblasts. Also disclosed are methods and compositions for treatment of erectile dysfunction using regenerative fibroblast-conditioned media. Regenerative fibroblast cells generated from fibroblasts and regenerative fibroblast-conditioned media are also described.

Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment, fibroblasts are cultured in an acidic pH incubation medium before genetic modification, after genetic modification, or both. In another embodiment, fibroblasts are cultured under hypoxic conditions. In another embodiment, fibroblasts are treated with mitogenic factor-comprising composition(s) to increase the efficacy of genetic modification, wherein the mitogenic factor(s) may be cytokines, peptides, and/or proteins. In another embodiment, a therapeutically effective amount of the genetically modified fibroblasts are provided as a therapeutic application to an individual in need thereof. In another embodiment, the therapeutic application is treatment of fibrosis, treatment of inflammation, acceleration of healing, treatment of clotting disorders, or promotion of angiogenesis.

Disclosed are compositions of matter, cells, protocols and procedures useful for augmentation of one or more therapeutic activities of fibroblast cellular populations. In one embodiment, fibroblasts are cultured in an acidic pH incubation medium before genetic modification, after genetic modification, or both. In another embodiment, fibroblasts are cultured under hypoxic conditions. In another embodiment, fibroblasts are treated with mitogenic factor-comprising composition(s) to increase the efficacy of genetic modification, wherein the mitogenic factor(s) may be cytokines, peptides, and/or proteins. In another embodiment, a therapeutically effective amount of the genetically modified fibroblasts are provided as a therapeutic application to an individual in need thereof. In another embodiment, the therapeutic application is treatment of fibrosis, treatment of inflammation, acceleration of healing, treatment of clotting disorders, or promotion of angiogenesis.

The invention generally relates to cells and compositions comprising same for use in cell therapy, to methods of obtaining same, and to use of same in cell therapy. In one aspect, the invention provides a method for forming a cell composition from a tissue sample, the method comprising: providing a tissue sample comprising cells; contacting the sample with a polymer in binding conditions, said binding conditions being conditions that enable binding of cells in the sample to the polymer, so that said cells are bound to the polymer; culturing the cells bound to the polymer under conditions and for a time that allows the cell number to increase; providing conditions to induce a phase change of the polymer; thereby forming a cell composition from a tissue sample.

Disclosed herein are methods and compositions for treating or preventing ovarian failure using fibroblasts or cells derived from fibroblasts. In some embodiments, ovarian failure is pathological, the result of an intervention, or the result of aging. In some embodiments, regenerative fibroblast cells are administered locally into the ovary or pen-ovary areas or systemically. In some embodiments, regenerative cells act to suppress fibrosis of the ovaries, inhibit inflammation, stimulate maturation of immature ovarian progenitor cells, or directly differentiate into oocytes. In some embodiments, regenerative fibroblasts produce factors that inhibit apoptosis of oocytes and/or oocyte progenitors.